Vedolizumab (new indication: antibiotic-resistant pouchitis, pre-treated patients)

Subject:

• Active Substance: Vedolizumab
• Name: Entyvio^®
• Therapeutic area: Antibiotic-resistant pouchitis
• Pharmaceutical company: Takeda GmbH

Time table:

• Start: 01.03.2022
• Final decision by G-BA: 01.09.2022

Final decision:

• No additional benefit proved